ArticlePediatric neurology2025
Clinical Characterization of a Multicenter International Cohort of Patients With Aicardi-Goutières Syndrome Homozygous for the RNASEH2B:p.Ala177Thr Variant: Early Clinical Markers of Disease Severity.
Article in Pediatric neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neurodegenerative Diseases in Children: A Comprehensive Review.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
Abstract
backgroundAicardi-Goutières syndrome (AGS) is a rare monogenic leukodystrophy belonging to type I interferonopathies caused by alterations in one of nine genes. Among them, homozygous RNASEH2B:c.529G>A(p.Ala177Thr) is the most common variant worldwide and associated to AGS2. This variant typically leads to severe phenotypes, but individuals with later onset or milder clinical manifestations have been described, with recent finding of asymptomatic homozygous individuals. However, the cause for this intragenotypic clinical variability is unclear, as well as developmental trajectories and early prognostic factors. Our study objective is the description of phenotypic variability in patients with AGS2 and the identification of early clinical markers of prognosis.
methodsA multicenter international retrospective natural history study was carried out by recruiting patients with AGS homozygous for p.Ala177Thr variant. Patients were categorized into three groups based on the clinical severity through the composite functional severity score, although comparison was made with the more recently introduced AGS severity score. Disease onset was divided into neonatal, infantile, and later onset. Demographic, clinical, and laboratory data were collected and compared between these groups.
resultsIrritability at onset correlates significantly to the three functional categories. Early age at onset and presence of extrapyramidal signs correlate to functional outcomes when comparing mild with severe patients. Furthermore, retrospective application of AGS severity score correlated well with the commonly used composite functional severity score.
conclusionThe authors observed irritability, early onset, and extrapyramidal signs not to be exclusive to the severe group, hence the need for creation of a composite predictive biomarker for prognosis accuracy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.